149 filings
Page 4 of 8
8-K
f7o g6uvou
6 Apr 20
Other Events
7:15am
8-K
sxhqv4 nppyikj2u
18 Mar 20
Departure of Directors or Certain Officers
8:00am
8-K
64bwsqr
27 Feb 20
Results of Operations and Financial Condition
7:30am
8-K
wifok62g6qpvov9g7pf7
21 Feb 20
Other Events
12:00am
8-K
8kc59e 7l
31 Jan 20
Other Events
4:06pm
8-K
louob4v3gh0 ebj3jt
6 Nov 19
Reports Third Quarter Financial Results
8:30am
8-K
cvob9wlvlb 6203k
29 Aug 19
Other Events
4:30pm
8-K
36gd pehjcj1hc6w
8 Aug 19
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
8:00am
8-K
bvo37e
26 Jun 19
Esperion and Oberland Capital Announce $200 Million Funding Agreement
5:18pm
8-K
r29lgc
30 May 19
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
1oaooo5yiuo05k dg
30 May 19
Departure of Directors or Certain Officers
4:30pm
8-K
vhba7hmvjin41d3u
8 May 19
Reports First Quarter Financial Results
8:01am
8-K
nm1hw63
6 May 19
Other Events
4:30pm
8-K
eexiim
28 Feb 19
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
4:45pm
8-K
dgvtkewqpqqy8wu5
4 Jan 19
Entry into a Material Definitive Agreement
7:45am
8-K
8af4sbze482ziv0e8
21 Dec 18
Departure of Directors or Certain Officers
5:03pm
8-K
xfgm0 98t3ep
1 Nov 18
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
4:17pm
8-K
497vrsi1nbzf
29 Oct 18
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
7:45am
8-K
za1 bbruyo736h
27 Aug 18
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
12:00am
8-K
nh5asmv2j
2 Aug 18
Results of Operations and Financial Condition
7:31am